KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Nat Commun · 2026-Mar-14 · PMID 41826281

Panel C质量警告待 EXE 对齐验证

Progression-free survival

Fig. 4. Progression-free survival by PD-L1 expression. Kaplan–Meier estimate in subgroups of PD-L1 CPS1 ( A ), PD-L1 CPS≥1 ( B ), PD-L1 CPS≥10 ( C ), and subgroup analysis ( D ). Source data are provided as a Source data file.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.44
质量通过否
预期曲线2
实际曲线1
X 范围0 – 36
Y 范围0 – 105

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

匹配 11 行
Curve序号X (norm)Y (norm)X (real)Y (real)X (pixel)Y (pixel)
110.00000.95930.0000100.7317637
120.08070.93502.888998.17078910
130.08390.93503.000098.17079010
140.08700.93503.111198.17079110
150.09010.93503.222298.17079210
160.09320.93503.333398.17079310
170.09630.93503.444498.17079410
180.09940.93503.555698.17079510
190.10250.93503.666798.17079610
1100.10560.93503.777898.17079710
1110.10870.93503.888998.17079810
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T16:51:01+00:00